ACTIVE SPECIFIC IMMUNOTHERAPY FOR MELANOMA

描述(由申请人提供)：本基金的长期目标 一直在开发针对恶性肿瘤的有效治疗性疫苗 黑色素瘤。该项目的重点是对受辐射的生活进行评估 多价黑色素瘤细胞疫苗。该项目有四个具体目标： 1)我们将在AJCC第三阶段进行一项多中心随机第三阶段试验 黑色素瘤测试PMCV加卡介苗具有优越活性的假说 与安慰剂加卡介苗相比，延长无病生存期和总生存期 作为手术后的辅助剂。2)确定最佳的免疫反应 与PMCV受者在这一阶段登记的临床结果相关 三、庭审。我们的目标是开发一种免疫反应模型，可以作为 用于监测黑色素瘤患者疫苗治疗的原型。 3)确定针对肿瘤相关抗原的免疫反应 可通过结合PMCV免疫疗法和细胞因子 诱导动物肿瘤排斥反应的有效疫苗佐剂 GMCSF、IL-12等模型及是否操纵共刺激 黑色素瘤细胞上的分子可以增强免疫原性。4)确定 新的肿瘤标志物能否用于检测亚临床转移 并量化对辅助治疗的反应。我们假设 这些新技术将有助于预测佐剂的疗效。 对没有临床证据的黑色素瘤患者的治疗 在甜食之后。

DESCRIPTION (provided by applicant): The long-term objective of this grant has been the development of effective therapeutic vaccines against malignant melanoma. The Project's focus is the evaluation of a living irradiated polyvalent melanoma cell vaccine (PMCV). This project has four Specific Aims: 1) We will conduct a multicenter randomized Phase III trial in AJCC Stage III melanoma to test the hypothesis that PMCV plus BCG has superior activity in prolonging disease free and overall survival when compared to placebo plus BCG as a post surgical adjuvant. 2) Determine the immune response that optimally correlates with the clinical outcome of PMCV recipients enrolled in the Phase III trial. Our goal is to develop an immune response model that can serve as a prototype for monitoring vaccine therapy in patients with melanoma. 3) Determine whether the immune response against tumor-associated antigens can be enhanced by combining PMCV immunotherapy with cytokines that are effective vaccine adjuvants for inducing tumor rejection responses in animal models, such as GMCSF and IL-12 and whether manipulation of co-stimulatory molecules on melanoma cells can enhance immmunogenicity. 4) To determine whether new tumor markers can be used to detect subclinical metastatic melanoma and quantitate the response to adjuvant therapy. We hypothesize that these new techniques will be useful in predicting the outcome of adjuvant therapy for melanoma patients who have no clinical evidence of disease following sugery.